Compare Novavax Inc (NVAX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Western Alliance Bancorporation — how do they compare? Novavax Inc trades at $7.95 (market cap $1.30B), while Western Alliance Bancorporation trades at $81.46 (market cap $8.78B). The key difference: Western Alliance Bancorporation is far larger — about 6.8× Novavax Inc's market cap, and Western Alliance Bancorporation pays a 2.09% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WAL | |
|---|---|---|
Market Cap | $1.30B | $8.78B |
Sector | Health | Financials |
52-Week High | $11.19 | $96.08 |
52-Week Low | $6.22 | $66.70 |
Enterprise Value | $879.40M | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Western Alliance Bancorporation (WAL) trades at $81.39, up 0.06% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.08, net income margin of 25.43%, and consistent earnings beats in recent quarters. Recent developments include the launch of WA VenueX, a digital asset liquidity platform, and recognition as Arizona's top bank by Forbes in 2026.
Outlook remains positive with a consensus price target of $93.86, implying 15% upside, supported by 79% analyst buy ratings. Risks include negative operating cash flow and institutional selling, but revenue growth and profitability trends provide a solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
